As β-blockers have been proven beneficial in attenuating or improving LV dysfunction in advanced-stage DMD patients [35], their early introduction in addition to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) may be therapeutically beneficial. This evidence concerns the gene ACE and Duchenne muscular dystrophy.